Looking towards the future, sex differences in hypertension, cardiovascular and kidney pathogenesis might provide new opportunities to develop novel therapies that not only suppress the classical AGT/renin/ACE/Ang II/AT1 receptor responses, but also restore the vasoprotective axis of the ACE2/Ang (1-7)/MasR/AT2 receptor responses. This evidence concerns the gene AGTR2 and hypertensive disorder.